{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:30:56Z","timestamp":1786656656651,"version":"build-2736575974"},"reference-count":305,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41585-025-01107-6","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:23:02Z","timestamp":1762788182000},"page":"395-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer"],"prefix":"10.1038","volume":"23","author":[{"given":"Sola","family":"Adeleke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao R.","family":"Galante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5373-1777","authenticated-orcid":false,"given":"Gurdip","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athar","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshed","family":"Bomanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-159X","authenticated-orcid":false,"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-8134","authenticated-orcid":false,"given":"Gary J. R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"1107_CR1","unstructured":"European Association of Urology. Epidemiology and aetiology. EAU https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/epidemiology-and-aetiology (2023)."},{"key":"1107_CR2","unstructured":"World Health Organization. Cancer today. IARC https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=population&types=1&cancers=27&group_populations=0&multiple_populations=1&sexes=1 (2022)."},{"key":"1107_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-024-01410-w","volume":"23","author":"U R\u00f6nning\u00e5s","year":"2024","unstructured":"R\u00f6nning\u00e5s, U., Holm, M., Fransson, P., Beckman, L. & Wennman-Larsen, A. Symptoms and quality of life among men starting treatment for metastatic castration-resistant prostate cancer \u2014 a prospective multicenter study. BMC Palliat. Care 23, 80 (2024).","journal-title":"BMC Palliat. Care"},{"key":"1107_CR4","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1080\/14796694.2025.2510890","volume":"21","author":"R Jain","year":"2025","unstructured":"Jain, R. et al. Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey. Future Oncol. 21, 2053\u20132066 (2025).","journal-title":"Future Oncol."},{"key":"1107_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1152\/ajpcell.00506.2004","volume":"288","author":"AK Rajasekaran","year":"2005","unstructured":"Rajasekaran, A. K., Anilkumar, G. & Christiansen, J. J. Is prostate-specific membrane antigen a multifunctional protein? Am. J. Physiol. Cell Physiol. 288, 975 (2005).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1107_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22594-1","volume":"8","author":"S Bravaccini","year":"2018","unstructured":"Bravaccini, S. et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci. Rep. 8, 4254 (2018).","journal-title":"Sci. Rep."},{"key":"1107_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","volume":"26","author":"MK Bakht","year":"2018","unstructured":"Bakht, M. K. et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr. Relat. Cancer 26, 131\u2013146 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"1107_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3389\/fonc.2018.00623","volume":"8","author":"MC Hupe","year":"2018","unstructured":"Hupe, M. C. et al. Expression of Prostate-Specific Membrane Antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front. Oncol. 8, 623 (2018).","journal-title":"Front. Oncol."},{"key":"1107_CR9","unstructured":"[No authors listed] FDA approves first PSMA-targeted PET drug. J. Nucl. Med. 62, 11N (2021)."},{"key":"1107_CR10","unstructured":"US Food and Drug Administration. FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. FDA https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer (2021)."},{"key":"1107_CR11","unstructured":"ASCO Post Staff. FDA approves flotufolastat fluorine-18 injection, first radiohybrid PSMA-targeted PET imaging agent for prostate cancer. ASCO Post https:\/\/ascopost.com\/news\/may-2023\/fda-approves-flotufolastat-fluorine-18-injection-first-radiohybrid-psma-targeted-pet-imaging-agent-for-prostate-cancer (2023)."},{"key":"1107_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.119.234922","volume":"61","author":"A Wurzer","year":"2020","unstructured":"Wurzer, A. et al. Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors. J. Nucl. Med. 61, 735\u2013742 (2020).","journal-title":"J. Nucl. Med."},{"key":"1107_CR13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2967\/jnumed.120.260091","volume":"62","author":"I Rauscher","year":"2021","unstructured":"Rauscher, I. et al. Detection efficacy of 18F-rhPSMA-7.3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment. J. Nucl. Med. 62, 1719\u20131726 (2021).","journal-title":"J. Nucl. Med."},{"key":"1107_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12734-4","volume":"24","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Diagnostic efficacy of [99mTc]Tc-PSMA SPECT\/CT for prostate cancer: a meta-analysis. BMC Cancer 24, 982 (2024).","journal-title":"BMC Cancer"},{"key":"1107_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.eururo.2022.03.002","volume":"82","author":"HA de Barros","year":"2022","unstructured":"de Barros, H. A. et al. Robot-assisted prostate-specific membrane antigen-radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: the first prospective feasibility study. Eur. Urol. 82, 97\u2013105 (2022).","journal-title":"Eur. Urol."},{"key":"1107_CR16","unstructured":"Medicines and Healthcare products Regulatory Agency. World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in men. MHRA https:\/\/www.gov.uk\/government\/news\/world-first-as-mhra-approves-trofolastat-for-diagnostic-imaging-of-prostate-cancer-in-men (2025)."},{"key":"1107_CR17","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.3390\/diagnostics13152542","volume":"13","author":"V Pant","year":"2023","unstructured":"Pant, V., Vinjamuri, S., Zanial, A. Z. & Naeem, F. Lessons from a 3-year review of PSMA PET-CT in a tertiary setting: can we fine tune referral criteria by identifying factors predicting positivity and negativity? Diagnostics 13, 2542 (2023).","journal-title":"Diagnostics"},{"key":"1107_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijrobp.2024.08.045","volume":"121","author":"C Udovicich","year":"2025","unstructured":"Udovicich, C. et al. Evolving paradigms in prostate cancer: the integral role of prostate-specific membrane antigen positron emission tomography\/computed tomography in primary staging and therapeutic decision-making. Int. J. Radiat. Oncol. Biol. Phys. 121, 307\u2013316 (2025).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1107_CR19","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00259-024-06594-0","volume":"51","author":"ML Donswijk","year":"2024","unstructured":"Donswijk, M. L. et al. The accuracy and intra- and interobserver variability of PSMA PET\/CT for the local staging of primary prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 51, 1741\u20131752 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1107_CR20","unstructured":"National Center for Biotechnology Information. Molecular Imaging and Contrast Agent Database (MICAD) (NCBI, 2013)."},{"key":"1107_CR21","first-page":"S13","volume":"6","author":"SS Chang","year":"2004","unstructured":"Chang, S. S. Overview of prostate-specific membrane antigen. Rev. Urol. 6, S13\u2013S18 (2004).","journal-title":"Rev. Urol."},{"key":"1107_CR22","volume":"2","author":"S Sengupta","year":"2019","unstructured":"Sengupta, S., Asha Krishnan, M., Chattopadhyay, S. & Chelvam, V. Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer. Cancer Rep. 2, e1169 (2019).","journal-title":"Cancer Rep."},{"key":"1107_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1200\/JCO.2023.41.6_suppl.154","volume":"41","author":"MN Stein","year":"2023","unstructured":"Stein, M. N. et al. Preliminary results from a phase 1\/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 41, 154 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR24","doi-asserted-by":"publisher","first-page":"TPS284","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS284","volume":"41","author":"W Kelly","year":"2023","unstructured":"Kelly, W. et al. A phase 1\/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 41, TPS284 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"H-D Hummel","year":"2021","unstructured":"Hummel, H.-D. et al. Pasotuxizumab, a BiTE immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings. Immunotherapy 13, 125\u2013141 (2021).","journal-title":"Immunotherapy"},{"key":"1107_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1158\/1078-0432.CCR-22-1601","volume":"29","author":"UN Vaishampayan","year":"2023","unstructured":"Vaishampayan, U. N. et al. Phase II trial of pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 29, 122\u2013133 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR27","doi-asserted-by":"publisher","first-page":"530.e15","DOI":"10.1016\/j.urolonc.2016.07.005","volume":"34","author":"MI Milowsky","year":"2016","unstructured":"Milowsky, M. I. et al. Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol. Oncol. 34, 530.e15\u2013530.e21 (2016).","journal-title":"Urol. Oncol."},{"key":"1107_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis, A. et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur. Urol. 76, 469\u2013478 (2019).","journal-title":"Eur. Urol."},{"key":"1107_CR29","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"1107_CR30","doi-asserted-by":"crossref","unstructured":"Alpen, E. L. in Radiation Biophysics 2nd edn 1\u201310 (Academic, 1998).","DOI":"10.1016\/B978-012053085-4\/50003-X"},{"key":"1107_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.semnuclmed.2008.05.002","volume":"38","author":"AI Kassis","year":"2008","unstructured":"Kassis, A. I. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin. Nucl. Med. 38, 358\u2013366 (2008).","journal-title":"Semin. Nucl. Med."},{"key":"1107_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","volume":"33","author":"Y-S Kim","year":"2012","unstructured":"Kim, Y.-S. & Brechbiel, M. W. An overview of targeted alpha therapy. Tumor Biol. 33, 573\u2013590 (2012).","journal-title":"Tumor Biol."},{"key":"1107_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088239","volume":"9","author":"F Graf","year":"2014","unstructured":"Graf, F. et al. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PLoS ONE 9, e88239 (2014).","journal-title":"PLoS ONE"},{"key":"1107_CR34","doi-asserted-by":"publisher","first-page":"848.e9","DOI":"10.1016\/j.urolonc.2020.05.028","volume":"38","author":"JS Batra","year":"2020","unstructured":"Batra, J. S. et al. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. Urol. Oncol. 38, 848.e9\u2013848.e16 (2020).","journal-title":"Urol. Oncol."},{"key":"1107_CR35","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/molecules25071743","volume":"25","author":"M Czerwi\u0144ska","year":"2020","unstructured":"Czerwi\u0144ska, M., Bilewicz, A., Kruszewski, M., Wegierek-Ciuk, A. & Lankoff, A. Targeted radionuclide therapy of prostate cancer-from basic research to clinical perspectives. Molecules 25, 1743 (2020).","journal-title":"Molecules"},{"key":"1107_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/ph8020321","volume":"8","author":"R de Kruijff","year":"2015","unstructured":"de Kruijff, R., Wolterbeek, H. & Denkova, A. A critical review of alpha radionuclide therapy \u2014 how to deal with recoiling daughters? Pharmaceuticals 8, 321\u2013336 (2015).","journal-title":"Pharmaceuticals"},{"key":"1107_CR37","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/pharmaceutics13060906","volume":"13","author":"R Eychenne","year":"2021","unstructured":"Eychenne, R., Ch\u00e9rel, M., Haddad, F., Gu\u00e9rard, F. & Gestin, J.-F. Overview of the most promising radionuclides for targeted alpha therapy: the \u201cHopeful Eight\u201d. Pharmaceutics 13, 906 (2021).","journal-title":"Pharmaceutics"},{"key":"1107_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","volume":"6","author":"S Golan","year":"2023","unstructured":"Golan, S. et al. Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial. Eur. Urol. Oncol. 6, 151\u2013159 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1107_CR39","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2967\/jnumed.123.267189","volume":"65","author":"MR Griffiths","year":"2024","unstructured":"Griffiths, M. R. et al. First-in-human 212Pb-PSMA-targeted \u03b1-therapy SPECT\/CT imaging in a patient with metastatic castration-resistant prostate cancer. J. Nucl. Med. 65, 664 (2024).","journal-title":"J. Nucl. Med."},{"key":"1107_CR40","unstructured":"ARTBIO. FogPharma and ARTBIO announce collaboration to co-develop multiple Helicon-enabled alpha-particle radioligand therapies for the treatment of cancer. ARTBIO https:\/\/artbio.com\/fogpharma-and-artbio-announce-collaboration-to-co-develop-multiple-helicon-enabled-alpha-particle-radioligand-therapies-for-the-treatment-of-cancer (2024)."},{"key":"1107_CR41","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2967\/jnumed.124.268101","volume":"65","author":"A Saidi","year":"2024","unstructured":"Saidi, A., Stallons, T. A., Wong, A. G. & Torgue, J. J. Preclinical investigation of [212Pb]Pb-DOTAM-GRPR1 for peptide receptor radionuclide therapy in a prostate tumor model. J. Nucl. Med. 65, 1769\u20131775 (2024).","journal-title":"J. Nucl. Med."},{"key":"1107_CR42","unstructured":"Oranomed. A diverse pipeline of 212Pb-labeled compounds. Oranomed https:\/\/www.oranomed.com\/en\/pipeline (2025)."},{"key":"1107_CR43","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1200\/JCO.23.00573","volume":"42","author":"ST Tagawa","year":"2024","unstructured":"Tagawa, S. T. et al. Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of 225Ac-J591. J. Clin. Oncol. 42, 842\u2013851 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR44","doi-asserted-by":"publisher","first-page":"TPS288","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS288","volume":"41","author":"JT Nauseef","year":"2023","unstructured":"Nauseef, J. T. et al. A phase I\/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA. J. Clin. Oncol. 41, TPS288 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR45","unstructured":"Clarke, A. FDA clears IND for 225Ac-J591 in advanced prostate cancer. Urology Times https:\/\/www.urologytimes.com\/view\/fda-clears-ind-for-225ac-j591-in-advanced-prostate-cancer (2024)."},{"key":"1107_CR46","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04946370 (2025)."},{"key":"1107_CR47","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04597411 (2025)."},{"key":"1107_CR48","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2023.41.6_suppl.181","volume":"41","author":"MP Sun","year":"2023","unstructured":"Sun, M. P. et al. Phase I results of a phase I\/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591. J. Clin. Oncol. 41, 181\u2013181 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11900-y","volume":"24","author":"SW Ling","year":"2024","unstructured":"Ling, S. W. et al. Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study. BMC Cancer 24, 146 (2024).","journal-title":"BMC Cancer"},{"key":"1107_CR50","unstructured":"Full-Life Technologies. Full-life technologies granted FDA fast track designation for 225Ac-FL-020 for the treatment of metastatic castration-resistant prostate cancer. Full-Life Technologies https:\/\/www.full-life.com\/media\/press-releases\/27 (2024)."},{"key":"1107_CR51","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1078-0432.CCR-19-2268","volume":"26","author":"S Hammer","year":"2020","unstructured":"Hammer, S. et al. Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer. Clin. Cancer Res. 26, 1985\u20131996 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR52","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03724747 (2024)."},{"key":"1107_CR53","doi-asserted-by":"crossref","unstructured":"Delpassand, I. S. et al. Preliminary efficacy and safety results from the TATCIST trial: a PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer. Presented at the American Association for Cancer Research Annual Meeting (2024).","DOI":"10.1158\/1538-7445.AM2024-CT224"},{"key":"1107_CR54","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05983198 (2025)."},{"key":"1107_CR55","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS282","volume":"43","author":"R Saleh","year":"2025","unstructured":"Saleh, R. et al. ACCEL: [Ac-225]-PSMA-62 phase Ia\/Ib\/II clinical trial to characterize efficacy, safety, tolerability, and dosimetry in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer. J. Clin. Oncol. 43, 842\u2013851 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR56","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06881823 (2025)."},{"key":"1107_CR57","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06855277 (2025)."},{"key":"1107_CR58","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06402331 (2025)."},{"key":"1107_CR59","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06780670 (2025)."},{"key":"1107_CR60","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04225910 (2020)."},{"key":"1107_CR61","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05902247 (2023)."},{"key":"1107_CR62","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06217822 (2025)."},{"key":"1107_CR63","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06052306 (2025)."},{"key":"1107_CR64","unstructured":"Klaassen, Z. PSMA and beyond 2025: overview of clinical trials of PSMA RLT in 2025. UroToday https:\/\/www.urotoday.com\/conference-highlights\/2025-ucsf-ucla-psma-conference\/159332-psma-and-beyond-2025-overview-of-clinical-trials-of-psma-rlt-in-2025.html (2025)."},{"key":"1107_CR65","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros, G., Bodei, L., McDevitt, M. R. & Nedrow, J. R. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat. Rev. Drug Discov. 19, 589\u2013608 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1107_CR66","unstructured":"US Food and Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer (2022)."},{"key":"1107_CR67","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich, U. & Eder, M. [177Lu]Lu-PSMA-617 (Pluvicto): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals 15, 1292 (2022).","journal-title":"Pharmaceuticals"},{"key":"1107_CR68","doi-asserted-by":"publisher","first-page":"LBA21","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA21","volume":"41","author":"ST Tagawa","year":"2023","unstructured":"Tagawa, S. T. et al. Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC). J. Clin. Oncol. 41, LBA21 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR69","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.32072","volume":"125","author":"ST Tagawa","year":"2019","unstructured":"Tagawa, S. T. et al. Phase 1\/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer. Cancer 125, 2561\u20132569 (2019).","journal-title":"Cancer"},{"key":"1107_CR70","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","volume":"23","author":"NH Bander","year":"2005","unstructured":"Bander, N. H. et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 23, 4591\u20134601 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR71","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/cncr.24795","volume":"116","author":"ST Tagawa","year":"2010","unstructured":"Tagawa, S. T. et al. Anti-prostate specific membrane antigen-based radioimmunotherapy for prostate. Cancer 116, 1075\u20131083 (2010).","journal-title":"Cancer"},{"key":"1107_CR72","first-page":"3629","volume":"57","author":"H Liu","year":"1997","unstructured":"Liu, H. et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57, 3629\u20133634 (1997).","journal-title":"Cancer Res."},{"key":"1107_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-016-0164-0","volume":"6","author":"EK Fung","year":"2016","unstructured":"Fung, E. K. et al. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Res. 6, 7 (2016).","journal-title":"EJNMMI Res."},{"key":"1107_CR74","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa, S. T. et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin. Cancer Res. 19, 5182\u20135191 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR75","unstructured":"National Cancer Institute. Lutetium Lu 177 rsopatamab tetraxetan. NCI https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/lutetium-lu-177-rosopatamab-tetraxetan (2023)."},{"key":"1107_CR76","unstructured":"Telix Pharmaceuticals. First patient dosed in phase III ProstACT GLOBAL study of antibody-based prostate cancer therapy candidate, TLX591. TelixPharmaceuticals https:\/\/telixpharma.com\/news-views\/first-patient-dosed-in-phase-iii-prostact-global-study-of-antibody-based-prostate-cancer-therapy-candidate-tlx591 (2023)."},{"key":"1107_CR77","unstructured":"Telix Pharmaceuticals. Telix announces positive rPFS data from ProstACT SELECT trial of TLX591 rADC therapy candidate in prostate cancer. PR Newswire https:\/\/www.prnewswire.com\/apac\/news-releases\/telix-announces-positive-rpfs-data-from-prostact-select-trial-of-tlx591-radc-therapy-candidate-in-prostate-cancer-302160140.html (2024)."},{"key":"1107_CR78","first-page":"1479","volume":"44","author":"AI Kassis","year":"2003","unstructured":"Kassis, A. I. Cancer therapy with Auger electrons: are we almost there? J. Nucl. Med. 44, 1479\u20131481 (2003).","journal-title":"J. Nucl. Med."},{"key":"1107_CR79","first-page":"861","volume":"18","author":"L Bodei","year":"2003","unstructured":"Bodei, L., Kassis, A. I., Adelstein, S. J. & Mariani, G. Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications. Cancer Biother. Radiopharm. 18, 861\u2013877 (2003).","journal-title":"Cancer Biother. Radiopharm."},{"key":"1107_CR80","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","volume":"46","author":"C M\u00fcller","year":"2019","unstructured":"M\u00fcller, C. et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 46, 1919\u20131930 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1107_CR81","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","volume":"26","author":"JP Buteau","year":"2025","unstructured":"Buteau, J. P. et al. First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta\u2013Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study. Lancet Oncol. 26, 1009\u20131017 (2025).","journal-title":"Lancet Oncol."},{"key":"1107_CR82","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s00259-024-07009-w","volume":"52","author":"A Chirindel","year":"2025","unstructured":"Chirindel, A. et al. First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study. Eur. J. Nucl. Med. Mol. Imaging 52, 1628\u20131630 (2025).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1107_CR83","first-page":"1","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal. Transduct. Target. Ther. 7, 1\u201325 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1107_CR84","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-20-4528","volume":"27","author":"JS de Bono","year":"2021","unstructured":"de Bono, J. S. et al. Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody\u2013drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide. Clin. Cancer Res. 27, 3602\u20133609 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR85","doi-asserted-by":"publisher","first-page":"S974","DOI":"10.1016\/j.annonc.2023.09.2752","volume":"34","author":"J Shen","year":"2023","unstructured":"Shen, J. et al. 1804P APEX-01: first-in-human phase I\/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol. 34, S974\u2013S975 (2023).","journal-title":"Ann. Oncol."},{"key":"1107_CR86","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","volume":"14","author":"Y Chu","year":"2021","unstructured":"Chu, Y., Zhou, X. & Wang, X. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J. Hematol. Oncol. 14, 88 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"1107_CR87","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li, F. et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 76, 2710\u20132719 (2016).","journal-title":"Cancer Res."},{"key":"1107_CR88","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer. N. Engl. J. Med. 382, 610\u2013621 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR89","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S. A. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401, 105\u2013117 (2023).","journal-title":"Lancet"},{"key":"1107_CR90","unstructured":"US Food and Drug Administraton. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer (2019)."},{"key":"1107_CR91","unstructured":"Daiichi-Sankyo. ENHERTU approved in the US as first tumor agnostic HER2 directed therapy for previously treated patients with metastatic HER2 positive solid tumors. Daiichi-Sankyo https:\/\/daiichisankyo.us\/press-releases\/-\/article\/enhertu-approved-in-the-u-s-as-first-tumor-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumors (2024)."},{"key":"1107_CR92","unstructured":"ecancer. FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies. ecancer https:\/\/ecancer.org\/en\/news\/17123-fda-approves-new-treatment-option-for-patients-with-her2-positive-breast-cancer-who-have-progressed-on-available-therapies (2020)."},{"key":"1107_CR93","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1535-7163.MCT-17-0982","volume":"17","author":"S Cho","year":"2018","unstructured":"Cho, S. et al. Antitumor activity of MEDI3726 (ADCT-401), a pyrrolobenzodiazepine antibody\u2013drug conjugate targeting PSMA, in preclinical models of prostate cancer. Mol. Cancer Ther. 17, 2176\u20132186 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"1107_CR94","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/pros.23765","volume":"79","author":"DP Petrylak","year":"2019","unstructured":"Petrylak, D. P. et al. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. Prostate 79, 604\u2013613 (2019).","journal-title":"Prostate"},{"key":"1107_CR95","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/pros.23922","volume":"80","author":"DP Petrylak","year":"2020","unstructured":"Petrylak, D. P. et al. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: efficacy and safety in open-label single-arm phase 2 study. Prostate 80, 99\u2013108 (2020).","journal-title":"Prostate"},{"key":"1107_CR96","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40, 1255\u20131263 (2022).","journal-title":"Cancer Cell"},{"key":"1107_CR97","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1158\/1538-7445.AM2023-3997","volume":"83","author":"L Skidmore","year":"2023","unstructured":"Skidmore, L. et al. Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer [abstract 3997]. Cancer Res. 83, 3997 (2023).","journal-title":"Cancer Res."},{"key":"1107_CR98","unstructured":"Ambrx Biopharma. FDA grants fast track designation for Ambrx\u2019s ARX517 for the treatment of metastatic castration-resistant prostate cancer. GlobeNewswire https:\/\/www.globenewswire.com\/news-release\/2023\/07\/19\/2707358\/0\/en\/FDA-Grants-Fast-Track-Designation-for-Ambrx-s-ARX517-for-the-Treatment-of-Metastatic-Castration-Resistant-Prostate-Cancer.html (2023)."},{"key":"1107_CR99","unstructured":"Klaassen, Z. APEX-01: first-in-human phase 1\/2 study of ARX517, an anti-PSMA ADC, in patients with mCRPC. UroToday https:\/\/www.urotoday.com\/conference-highlights\/esmo-2023\/esmo-2023-prostate-cancer\/147612-esmo-2023-apex-01-first-in-human-phase-1-2-study-of-arx517-an-anti-psma-adc-in-patients-with-mcrpc.html (2023)."},{"key":"1107_CR100","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/1535-7163.MCT-23-0927","volume":"23","author":"LK Skidmore","year":"2024","unstructured":"Skidmore, L. K. et al. Preclinical characterization of ARX517, a site-specific stable PSMA-targeted antibody-drug conjugate for the treatment of metastatic castration-resistant prostate cancer. Mol. Cancer Ther. 23, 1842\u20131853 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"1107_CR101","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93, 290\u2013296 (2015).","journal-title":"Immunol. Cell Biol."},{"key":"1107_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93842-0","volume":"11","author":"L Haber","year":"2021","unstructured":"Haber, L. et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci. Rep. 11, 14397 (2021).","journal-title":"Sci. Rep."},{"key":"1107_CR103","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian, Z., Liu, M., Zhang, Y. & Wang, X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J. Hematol. Oncol. 14, 75 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"1107_CR104","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma (2023)."},{"key":"1107_CR105","unstructured":"US Food and Drug Administration. FDA grants regular approval to blinatumomab and expands indication to include Philadelphia chromosome-positive B cell. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-blinatumomab-and-expands-indication-include-philadelphia-chromosome (2017)."},{"key":"1107_CR106","unstructured":"US Food and Drug Administration. FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-blinatumomab-blincyto-amgen-inc-treatment-adult-and-pediatric (2018)."},{"key":"1107_CR107","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer (2024)."},{"key":"1107_CR108","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"M-J Ahn","year":"2023","unstructured":"Ahn, M.-J. et al. Tarlatamab for patients with previously treated small-cell lung cancer. N. Engl. J. Med. 389, 2063\u20132075 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR109","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","volume":"27","author":"P Deegen","year":"2021","unstructured":"Deegen, P. et al. The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer. Clin. Cancer Res. 27, 2928\u20132937 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR110","doi-asserted-by":"crossref","unstructured":"Tran, B. et al. Results from a phase I study of AMG 160, a half-life-extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) [abstract 609O]. Ann. Oncol. 31, S507 (2020).","DOI":"10.1016\/j.annonc.2020.08.869"},{"key":"1107_CR111","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04631601 (2025)."},{"key":"1107_CR112","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","volume":"30","author":"T Dorff","year":"2021","unstructured":"Dorff, T. et al. A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. Clin. Cancer Res. 30, 1488\u20131500 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR113","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002488","volume":"9","author":"K Dang","year":"2021","unstructured":"Dang, K. et al. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. J. Immunother. Cancer 9, e002488 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1107_CR114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14587","volume":"42","author":"GS Falchook","year":"2024","unstructured":"Falchook, G. S. et al. Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 42, e14587 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR115","doi-asserted-by":"publisher","first-page":"17123","DOI":"10.1021\/acs.jmedchem.1c01157","volume":"64","author":"AE Machulkin","year":"2021","unstructured":"Machulkin, A. E. et al. Synthesis, characterization, and preclinical evaluation of a small-molecule prostate-specific membrane antigen-targeted monomethyl auristatin E conjugate. J. Med. Chem. 64, 17123\u201317145 (2021).","journal-title":"J. Med. Chem."},{"key":"1107_CR116","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO-25-00678","volume":"43","author":"MN Stein","year":"2025","unstructured":"Stein, M. N. et al. Pasritamig, a first-in-class, bispecific T-Cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase 1 study. J. Clin. Oncol. 43, 2515\u20132526 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR117","doi-asserted-by":"publisher","first-page":"TPS5094","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5094","volume":"39","author":"M Markowski","year":"2021","unstructured":"Markowski, M. et al. Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 39, TPS5094 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR118","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1158\/1535-7163.MCT-20-0061","volume":"20","author":"RJ Austin","year":"2021","unstructured":"Austin, R. J. et al. TriTACs, a novel class of T-cell\u2013engaging protein constructs designed for the treatment of solid tumors. Mol. Cancer Ther. 20, 109\u2013120 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"1107_CR119","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/1535-7163.MCT-23-0524","volume":"23","author":"ME Molloy","year":"2024","unstructured":"Molloy, M. E. et al. HPN328, a trispecific T cell\u2013activating protein construct targeting DLL3-expressing solid tumors. Mol. Cancer Ther. 23, 1294\u20131304 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"1107_CR120","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1200\/JCO.2020.38.15_suppl.5552","volume":"38","author":"JC Bendell","year":"2020","unstructured":"Bendell, J. C. et al. First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 38, 5552\u20135552 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR121","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1200\/JCO.2021.39.15_suppl.5013","volume":"39","author":"BJS De","year":"2021","unstructured":"De, B. J. S. et al. Results of an ongoing phase 1\/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 39, 5013 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR122","unstructured":"Taylor, N. P. Regeneron rethinks CD28 bispecific R&D plan after 2 patients die. Fierce Biotech https:\/\/www.fiercebiotech.com\/biotech\/regeneron-rethinks-cd28-bispecific-rd-plan-after-2-patients-die (2023)."},{"key":"1107_CR123","unstructured":"Amgen. Teneobio acquisition adds talent and new types of antibodies to Amgen. Amgen https:\/\/www.amgen.com\/stories\/2022\/01\/teneobio-acquisition-adds-talent-and-new-types-of-antibodies-to-amgen (2022)."},{"key":"1107_CR124","unstructured":"US Food and Drug Administration. FDA approves tisagenlecleucel for relapsed or refractory follicular lymphoma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-relapsed-or-refractory-follicular-lymphoma (2022)."},{"key":"1107_CR125","unstructured":"US Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome (2017)."},{"key":"1107_CR126","unstructured":"US Food and Drug Administration. YESCARTA. FDA https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta (2025)."},{"key":"1107_CR127","unstructured":"US Food and Drug Administration. TECARTUS. FDA https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus (2025)."},{"key":"1107_CR128","unstructured":"US Food and Drug Administration. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma (2024)."},{"key":"1107_CR129","unstructured":"US Food and Drug Administration. FDA approves idecabtagene vicleucel for multiple myeloma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma (2021)."},{"key":"1107_CR130","unstructured":"US Food and Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma (2022)."},{"key":"1107_CR131","doi-asserted-by":"publisher","first-page":"9080","DOI":"10.1158\/0008-5472.CAN-05-0436","volume":"65","author":"TPF Gade","year":"2005","unstructured":"Gade, T. P. F. et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 65, 9080\u20139088 (2005).","journal-title":"Cancer Res."},{"key":"1107_CR132","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher, J., Brentjens, R. J., Gunset, G., Rivi\u00e8re, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor. Nat. Biotechnol. 20, 70\u201375 (2002).","journal-title":"Nat. Biotechnol."},{"key":"1107_CR133","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/pros.23214","volume":"76","author":"RP Junghans","year":"2016","unstructured":"Junghans, R. P. et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate 76, 1257\u20131270 (2016).","journal-title":"Prostate"},{"key":"1107_CR134","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1200\/JCO.2022.40.6_suppl.098","volume":"40","author":"SF Slovin","year":"2022","unstructured":"Slovin, S. F. et al. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 40, 98 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR135","unstructured":"Rosa, K. FDA halts phase 1 trial with P-PSMA-101 in mCRPC following patient death. OncLive https:\/\/www.onclive.com\/view\/fda-halts-phase-1-trial-with-p-psma-01-in-mcrpc-following-patient-death (2020)."},{"key":"1107_CR136","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha, I. et al. Management of adults and children undergoing CAR T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105,\u00a0297\u2013316 (2020).","journal-title":"Haematologica"},{"key":"1107_CR137","unstructured":"eviQ. Cytokine-release syndrome (CRS). eviQ https:\/\/www.eviq.org.au\/clinical-resources\/oncological-emergencies\/3500-cytokine-release-syndrome-associated-with-car#background (2025)."},{"key":"1107_CR138","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1200\/JCO.2025.43.5_suppl.128","volume":"43","author":"A Saxena","year":"2025","unstructured":"Saxena, A. et al. Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): a meta-analysis. J. Clin. Oncol. 43, 128\u2013128 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT0308 (2025)."},{"key":"1107_CR140","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04227275 (2023)."},{"key":"1107_CR141","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04768608 (2023)."},{"key":"1107_CR142","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05732948 (2023)."},{"key":"1107_CR143","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04633148 (2024)."},{"key":"1107_CR144","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","volume":"39","author":"Y Kfoury","year":"2021","unstructured":"Kfoury, Y. et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell 39, 1464\u20131478.e8 (2021).","journal-title":"Cancer Cell"},{"key":"1107_CR145","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR146","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219\u20132230 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR147","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR148","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1016\/j.clon.2023.07.009","volume":"35","author":"H Abdel-Aty","year":"2023","unstructured":"Abdel-Aty, H. et al. The STAMPEDE2 trial: a site survey of current patterns of care, access to imaging and treatment of metastatic prostate cancer. Clin. Oncol. 35, e628\u2013e635 (2023).","journal-title":"Clin. Oncol."},{"key":"1107_CR149","unstructured":"STAMPEDE2. STAMPEDE2: a randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer. STAMPEDE2 https:\/\/www.stampede2trial.org (2025)."},{"key":"1107_CR150","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121\u2013131 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR151","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR152","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith, M. R. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378, 1408\u20131418 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR153","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain, M. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 378, 2465\u20132474 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR154","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg, C. N. et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 382, 2197\u20132206 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR155","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fonc.2019.00801","volume":"9","author":"MA Rice","year":"2019","unstructured":"Rice, M. A., Malhotra, S. V. & Stoyanova, T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front. Oncol. 9, 801 (2019).","journal-title":"Front. Oncol."},{"key":"1107_CR156","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05084-1","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Zhou, Q., Hankey, W., Fang, X. & Yuan, F. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 13, 632 (2022).","journal-title":"Cell Death Dis."},{"key":"1107_CR157","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett, L. et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 25, 563\u2013571 (2024).","journal-title":"Lancet Oncol."},{"key":"1107_CR158","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1200\/JCO.2025.43.5_suppl.121","volume":"43","author":"O Yazdanpanah","year":"2025","unstructured":"Yazdanpanah, O. et al. Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis. J. Clin. Oncol. 43, 121\u2013121 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR159","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1200\/JCO.2025.43.5_suppl.112","volume":"43","author":"M Muniz","year":"2025","unstructured":"Muniz, M. et al. Outcomes for 177Lu-PSMA-617 with and without concurrent use of ARPIs in patients with mCRPC. J. Clin. Oncol. 43, 112\u2013112 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR160","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","volume":"24","author":"JC Morales","year":"2014","unstructured":"Morales, J. C. et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit. Rev. Eukaryot. Gene Expr. 24, 15\u201328 (2014).","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"1107_CR161","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697\u20131708 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR162","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.2967\/jnumed.120.243295","volume":"62","author":"S Sandhu","year":"2021","unstructured":"Sandhu, S., Guo, C. & Hofman, M. S. Radionuclide therapy in prostate cancer: from standalone to combination PSMA theranostics. J. Nucl. Med. 62, 1660\u20131668 (2021).","journal-title":"J. Nucl. Med."},{"key":"1107_CR163","doi-asserted-by":"publisher","first-page":"175628722412729","DOI":"10.1177\/17562872241272929","volume":"16","author":"MD Fenor de la Maza","year":"2024","unstructured":"Fenor de la Maza, M. D., P\u00e9rez Gracia, J. L., Mi\u00f1ana, B. & Castro, E. PARP inhibitors alone or in combination for prostate cancer. Ther. Adv. Urol. 16, 17562872241272928 (2024).","journal-title":"Ther. Adv. Urol."},{"key":"1107_CR164","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03874884 (2025)."},{"key":"1107_CR165","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","volume":"41","author":"S Sandhu","year":"2023","unstructured":"Sandhu, S. et al. LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 41, 5005 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR166","doi-asserted-by":"publisher","first-page":"8037","DOI":"10.3390\/ijms23148037","volume":"23","author":"EAM Ruigrok","year":"2022","unstructured":"Ruigrok, E. A. M. et al. Preclinical assessment of the combination of PSMA-targeting radionuclide therapy with PARP inhibitors for prostate cancer treatment. Int. J. Mol. Sci. 23, 8037 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1107_CR167","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1091\/mbc.8.2.287","volume":"8","author":"L Connell-Crowley","year":"1997","unstructured":"Connell-Crowley, L., Harper, J. W. & Goodrich, D. W. Cyclin D1\/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell 8, 287\u2013301 (1997).","journal-title":"Mol. Biol. Cell"},{"key":"1107_CR168","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.3390\/curroncol30060415","volume":"30","author":"R Franco","year":"2023","unstructured":"Franco, R., Cao, J. Q., Yassa, M. & Hijal, T. Safety of CDK4\/6 inhibitors combined with radiotherapy in patients with metastatic breast cancer: a review of the literature. Curr. Oncol. 30, 5485\u20135496 (2023).","journal-title":"Curr. Oncol."},{"key":"1107_CR169","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/cancers15030690","volume":"15","author":"M Kubeczko","year":"2023","unstructured":"Kubeczko, M. et al. Safety and feasibility of radiation therapy combined with CDK 4\/6 inhibitors in the management of advanced breast cancer. Cancers 15, 690 (2023).","journal-title":"Cancers"},{"key":"1107_CR170","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4\/6 inhibitors. Nat. Rev. Clin. Oncol. 13, 417\u2013430 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1107_CR171","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-15-2548","volume":"22","author":"DD Von Hoff","year":"2016","unstructured":"Von Hoff, D. D. et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin. Cancer Res. 22, 3157\u20133163 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR172","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05113537 (2025)."},{"key":"1107_CR173","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0093-7754(01)90148-4","volume":"28","author":"KJ Pienta","year":"2001","unstructured":"Pienta, K. J. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin. Oncol. 28, 3\u20137 (2001).","journal-title":"Semin. Oncol."},{"key":"1107_CR174","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/1758834017692779","volume":"9","author":"J Puente","year":"2017","unstructured":"Puente, J. et al. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther. Adv. Med. Oncol. 9, 307\u2013318 (2017).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1107_CR175","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bju.15384","volume":"128","author":"N Dhiantravan","year":"2021","unstructured":"Dhiantravan, N. et al. UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-na\u00efve prostate cancer (clinical trial protocol). BJU Int. 128, 331\u2013342 (2021).","journal-title":"BJU Int."},{"key":"1107_CR176","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad, A. A. et al. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 25, 1267\u20131276 (2024).","journal-title":"Lancet Oncol."},{"key":"1107_CR177","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/RLU.0000000000001763","volume":"42","author":"X Wei","year":"2017","unstructured":"Wei, X., Schlenkhoff, C., Schwarz, B., Essler, M. & Ahmadzadehfar, H. Combination of 177Lu-PSMA-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer. Clin. Nucl. Med. 42, 704\u2013706 (2017).","journal-title":"Clin. Nucl. Med."},{"key":"1107_CR178","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1107_CR179","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","volume":"11","author":"CG Drake","year":"2014","unstructured":"Drake, C. G., Lipson, E. J. & Brahmer, J. R. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat. Rev. Clin. Oncol. 11, 24\u201337 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1107_CR180","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner, M. C. et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat. Rev. Urol. 18, 79\u201392 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"1107_CR181","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","volume":"6","author":"SM Vareki","year":"2018","unstructured":"Vareki, S. M. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J. Immunother. Cancer 6, 157 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1107_CR182","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2214\/AJR.12.8510","volume":"198","author":"S Verma","year":"2012","unstructured":"Verma, S., Turkbey, B. & Muradyan, N. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am. J. Roentgenol. 198, 1277 (2012).","journal-title":"AJR Am. J. Roentgenol."},{"key":"1107_CR183","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991\u2013998 (2002).","journal-title":"Nat. Immunol."},{"key":"1107_CR184","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"1107_CR185","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2019","unstructured":"Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395\u2013405 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR186","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat. Med. 28, 144\u2013153 (2022).","journal-title":"Nat. Med."},{"key":"1107_CR187","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak, D. P. et al. Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial. J. Clin. Oncol. 43, 1638\u20131649 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR188","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05806814 (2025)."},{"key":"1107_CR189","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05568550 (2025)."},{"key":"1107_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05077098 (2025)."},{"key":"1107_CR191","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/1078-0432.CCR-22-2340","volume":"29","author":"AK Cheema","year":"2023","unstructured":"Cheema, A. K. et al. Radiotherapy induces innate immune responses in patients treated for prostate cancers. Clin. Cancer Res. 29, 921\u2013929 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR192","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41585-024-00913-8","volume":"21","author":"RS Eapen","year":"2024","unstructured":"Eapen, R. S. et al. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer. Nat. Rev. Urol. 21, 676\u2013686 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"1107_CR193","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41585-024-00924-5","volume":"21","author":"S Lunj","year":"2024","unstructured":"Lunj, S. et al. Immune effects of \u03b1 and \u03b2 radionuclides in metastatic prostate cancer. Nat. Rev. Urol. 21, 651\u2013661 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"1107_CR194","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2023.2173175","volume":"23","author":"RR Colciago","year":"2023","unstructured":"Colciago, R. R. et al. Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement. Expert Rev. Anticancer Ther. 23, 135\u2013145 (2023).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1107_CR195","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole, R. H. Whole body irradiation; radiobiology or medicine? Br. J. Radiol. 26, 234\u2013241 (1953).","journal-title":"Br. J. Radiol."},{"key":"1107_CR196","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria, S. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862\u2013870 (2004).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1107_CR197","doi-asserted-by":"publisher","first-page":"TPS271","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS271","volume":"41","author":"S Sandhu","year":"2023","unstructured":"Sandhu, S. et al. Evolution: phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). J. Clin. Oncol. 41, TPS271 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR198","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","volume":"40","author":"S Sandhu","year":"2022","unstructured":"Sandhu, S. et al. PRINCE: phase I trial of 177 Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 40, 5017 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR199","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal, R. et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 24, 1266\u20131276 (2023).","journal-title":"Lancet Oncol."},{"key":"1107_CR200","unstructured":"Sayyid, R. The current state of treatment implementation for mCRPC in North America. UroToday https:\/\/www.urotoday.com\/library-resources\/advanced-prostate-cancer\/147780-the-current-state-of-treatment-implementation-for-mcrpc-in-north-america.html (2023)."},{"key":"1107_CR201","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","volume":"50","author":"MV Pilepich","year":"2001","unstructured":"Pilepich, M. V. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243\u20131252 (2001).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1107_CR202","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","volume":"26","author":"M Roach","year":"2008","unstructured":"Roach, M. et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26, 585\u2013591 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR203","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","volume":"6","author":"JW Denham","year":"2005","unstructured":"Denham, J. W. et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 6, 841\u2013850 (2005).","journal-title":"Lancet Oncol."},{"key":"1107_CR204","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.euf.2020.09.021","volume":"7","author":"N Dhiantravan","year":"2021","unstructured":"Dhiantravan, N. et al. Clinical trial protocol for LuTectomy: a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to prostatectomy. Eur. Urol. Focus\u00a07, 234\u2013237 (2021).","journal-title":"Eur. Urol. Focus"},{"key":"1107_CR205","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1012348","volume":"365","author":"CU Jones","year":"2011","unstructured":"Jones, C. U. et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med. 365, 107\u2013118 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR206","unstructured":"National Institute for Health and Care Excellence. Locally Advanced Prostate Cancer (NICE, 2019)."},{"key":"1107_CR207","unstructured":"European Association of Urology. Prostace cancer \u2014 treatment. EAU https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment (2025)."},{"key":"1107_CR208","unstructured":"Klaassen, Z. EAU 2023: LuTectomy: a prospective study of dosimetry, safety and potential benefit of upfront 177Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with high-risk localized prostate cancer. UroToday https:\/\/www.urotoday.com\/conference-highlights\/eau-annual-congress-2023\/eau-2023-prostate-cancer\/143074-eau-2023-lutectomy-a-prospective-study-of-dosimetry-safety-and-potential-benefit-of-upfront-177lu-psma-617-radioligand-therapy-prior-to-radical-prostatectomy-in-men-with-high-risk-localized-prostate-cancer.html (2023)."},{"key":"1107_CR209","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen, R. S. et al. Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study. Eur. Urol. 85, 217\u2013226\u00a0(2024).","journal-title":"Eur. Urol."},{"key":"1107_CR210","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2021.04.005","volume":"80","author":"S Adeleke","year":"2021","unstructured":"Adeleke, S., Haroon, A. & Kasivisvanathan, V. Re: [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Eur. Urol. 80, 118\u2013119 (2021).","journal-title":"Eur. Urol."},{"key":"1107_CR211","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13046-022-02430-1","volume":"41","author":"X Bao","year":"2022","unstructured":"Bao, X. & Xie, L. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death. J. Exp. Clin. Cancer Res. 41, 222 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1107_CR212","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1080\/21645515.2020.1840254","volume":"17","author":"C Chen","year":"2021","unstructured":"Chen, C., Liu, Y. & Cui, B. Effect of radiotherapy on T cell and PD-1 \/ PD-L1 blocking therapy in tumor microenvironment. Hum. Vaccin. Immunother. 17, 1555\u20131567 (2021).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1107_CR213","doi-asserted-by":"publisher","first-page":"TPS352","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS352","volume":"42","author":"U Krafft","year":"2024","unstructured":"Krafft, U. et al. A randomized phase I\/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial). J. Clin. Oncol. 42, TPS352 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR214","doi-asserted-by":"publisher","first-page":"104604","DOI":"10.1016\/j.critrevonc.2024.104604","volume":"207","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management. Crit. Rev. Oncol. Hematol. 207, 104604 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1107_CR215","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000000295","volume":"202","author":"TM Pisansky","year":"2019","unstructured":"Pisansky, T. M., Thompson, I. M., Valicenti, R. K., D\u2019Amico, A. V. & Selvarajah, S. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO\/AUA guideline amendment 2018\u20132019. J. Urol. 202, 533\u2013538 (2019).","journal-title":"J. Urol."},{"key":"1107_CR216","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/21681805.2019.1702093","volume":"54","author":"G George","year":"2020","unstructured":"George, G. et al. Long-term adherence to GnRH agonists in men with prostate cancer: a nation-wide population-based study in prostate cancer data base Sweden. Scand. J. Urol. 54, 20\u201326 (2020).","journal-title":"Scand. J. Urol."},{"key":"1107_CR217","doi-asserted-by":"publisher","first-page":"66112","DOI":"10.18632\/oncotarget.19805","volume":"8","author":"FE von Eyben","year":"2017","unstructured":"von Eyben, F. E. et al. 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer. Oncotarget 8, 66112\u201366116 (2017).","journal-title":"Oncotarget"},{"key":"1107_CR218","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JCO.2025.43.5_suppl.172","volume":"43","author":"AB Arham","year":"2025","unstructured":"Arham, A. B. et al. Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC). J. Clin. Oncol. 43, 172\u2013172 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR219","doi-asserted-by":"publisher","first-page":"TPS210","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS210","volume":"40","author":"A Sartor","year":"2022","unstructured":"Sartor, A. et al. PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 40, TPS210 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR220","doi-asserted-by":"publisher","first-page":"423","DOI":"10.12688\/f1000research.52546.3","volume":"10","author":"F Petrelli","year":"2021","unstructured":"Petrelli, F. et al. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 10, 423 (2021).","journal-title":"F1000Res."},{"key":"1107_CR221","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J. Clin. Oncol. 38, 2830\u20132838 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR222","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","volume":"19","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. Nat. Rev. Urol. 19, 475\u2013493 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"1107_CR223","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446\u2013453 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR224","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen, P. L. et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur. Urol. 67, 825\u2013836 (2015).","journal-title":"Eur. Urol."},{"key":"1107_CR225","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","volume":"6","author":"B Cao","year":"2023","unstructured":"Cao, B., Kim, M., Reizine, N. M. & Moreira, D. M. Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis. Eur. Urol. Oncol. 6, 237\u2013250 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1107_CR226","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bju.15988","volume":"132","author":"TM Ma","year":"2023","unstructured":"Ma, T. M. et al. LUNAR: a randomized phase 2 study of 177Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol). BJU Int. 132, 65\u201374 (2023).","journal-title":"BJU Int."},{"key":"1107_CR227","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05079698 (2025)."},{"key":"1107_CR228","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05560659 (2025)."},{"key":"1107_CR229","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","volume":"27","author":"BM Priv\u00e9","year":"2021","unstructured":"Priv\u00e9, B. M. et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study. Clin. Cancer Res. 27, 3595\u20133601 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR230","unstructured":"Telix Pharmaceuticals. ProstACT update: TARGET study ethics approval. Telix Pharmaceuticals https:\/\/telixpharma.com\/news-views\/prostact-update-target-study-ethics-approval (2022)."},{"key":"1107_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07386-z","volume":"20","author":"BM Priv\u00e9","year":"2020","unstructured":"Priv\u00e9, B. M. et al. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer 20, 884 (2020).","journal-title":"BMC Cancer"},{"key":"1107_CR232","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.eururo.2021.06.012","volume":"80","author":"S Satapathy","year":"2021","unstructured":"Satapathy, S. et al. Short-course 177Lu-PSMA-617 radioligand therapy in high-volume metastatic hormone-sensitive prostate cancer: time to take the leap? Eur. Urol. 80, 390\u2013392 (2021).","journal-title":"Eur. Urol."},{"key":"1107_CR233","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1874471011666180604083911","volume":"11","author":"N Pfannkuchen","year":"2018","unstructured":"Pfannkuchen, N., Bausbacher, N., Pektor, S., Miederer, M. & Rosch, F. In vivo evaluation of [225Ac]Ac-DOTAZOL for \u03b1-Therapy of bone metastases. Curr. Radiopharm. 11, 223\u2013230 (2018).","journal-title":"Curr. Radiopharm."},{"key":"1107_CR234","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13\u201324 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1107_CR235","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi, K. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20, 686\u2013700 (2019).","journal-title":"Lancet Oncol."},{"key":"1107_CR236","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman, M. S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397, 797\u2013804 (2021).","journal-title":"Lancet"},{"key":"1107_CR237","doi-asserted-by":"publisher","first-page":"1059122","DOI":"10.3389\/fmed.2022.1059122","volume":"9","author":"L Kostos","year":"2022","unstructured":"Kostos, L. et al. AlphaBet: combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front. Med. 9, 1059122 (2022).","journal-title":"Front. Med."},{"key":"1107_CR238","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris, M. J. et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404, 1227\u20131239 (2024).","journal-title":"Lancet"},{"key":"1107_CR239","unstructured":"US Food and Drug Administration. FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication (2025)."},{"key":"1107_CR240","first-page":"1","volume":"42","author":"A Gafita","year":"2022","unstructured":"Gafita, A. et al. Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. Am. Soc. Clin. Oncol. Educ. Book\u00a042, 1\u201317 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1107_CR241","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","volume":"20","author":"MJ Roberts","year":"2023","unstructured":"Roberts, M. J. et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat. Rev. Urol. 20, 23\u201347 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"1107_CR242","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita, A. et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 22, 1115\u20131125 (2021).","journal-title":"Lancet Oncol."},{"key":"1107_CR243","doi-asserted-by":"publisher","first-page":"102862","DOI":"10.1016\/j.eclinm.2024.102862","volume":"77","author":"K Herrmann","year":"2024","unstructured":"Herrmann, K. et al. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. EClinicalMedicine 77, 102862 (2024).","journal-title":"EClinicalMedicine"},{"key":"1107_CR244","doi-asserted-by":"publisher","first-page":"644","DOI":"10.2967\/jnumed.118.215715","volume":"60","author":"A Gafita","year":"2019","unstructured":"Gafita, A. et al. Early experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with advanced prostate cancer. J. Nucl. Med. 60, 644\u2013648 (2019).","journal-title":"J. Nucl. Med."},{"key":"1107_CR245","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2967\/jnumed.123.267321","volume":"65","author":"R Seifert","year":"2024","unstructured":"Seifert, R. et al. Safety and efficacy of extended therapy with [177Lu]Lu-PSMA: a German multicenter study. J. Nucl. Med. 65, 909\u2013916 (2024).","journal-title":"J. Nucl. Med."},{"key":"1107_CR246","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","volume":"49","author":"IO Lawal","year":"2022","unstructured":"Lawal, I. O. et al. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 49, 3581\u20133592 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1107_CR247","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12149-019-01348-7","volume":"33","author":"A Khawar","year":"2019","unstructured":"Khawar, A. et al. Preliminary results of biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL: a new zoledronate-based bisphosphonate for PET\/CT diagnosis of bone diseases. Ann. Nucl. Med. 33, 404\u2013413 (2019).","journal-title":"Ann. Nucl. Med."},{"key":"1107_CR248","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/cancers17010093","volume":"17","author":"G Mazzucato","year":"2024","unstructured":"Mazzucato, G. et al. Robot-assisted PSMA-radioguided salvage surgery for oligorecurrent prostate cancer using the novel SENSEI drop-in gamma probe: correlation of intraoperative measurements to preoperative imaging and final histology. Cancers 17, 93 (2024).","journal-title":"Cancers"},{"key":"1107_CR249","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.eururo.2022.06.002","volume":"82","author":"G Gandaglia","year":"2022","unstructured":"Gandaglia, G. et al. Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: results of a planned interim analysis of a prospective phase 2 study. Eur. Urol. 82, 411\u2013418 (2022).","journal-title":"Eur. Urol."},{"key":"1107_CR250","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.urology.2023.08.013","volume":"182","author":"M Oderda","year":"2023","unstructured":"Oderda, M. et al. Robot-assisted PSMA-radioguided surgery to assess surgical margins and nodal metastases in prostate cancer patients: report on three cases using an intraoperative PET-CT specimen imager. Urology 182, e257\u2013e261 (2023).","journal-title":"Urology"},{"key":"1107_CR251","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1007\/s00259-025-07255-6","volume":"52","author":"A Di Giorgio","year":"2025","unstructured":"Di Giorgio, A. et al. Long-term outcomes of PSMA PET\/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis. Eur. J. Nucl. Med. Mol. Imaging 52, 3720\u20133729 (2025).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1107_CR252","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05555017 (2023)."},{"key":"1107_CR253","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.euf.2020.12.010","volume":"7","author":"T Zilli","year":"2021","unstructured":"Zilli, T. et al. The multicenter, randomized, phase 2 PEACE V-STORM trial: defining the best salvage treatment for oligorecurrent nodal prostate cancer metastases. Eur. Urol. Focus\u00a07, 241\u2013244 (2021).","journal-title":"Eur. Urol. Focus"},{"key":"1107_CR254","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","volume":"83","author":"S Knipper","year":"2023","unstructured":"Knipper, S. et al. Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen\u2013radioguided surgery. Eur. Urol. 83, 62\u201369 (2023).","journal-title":"Eur. Urol."},{"key":"1107_CR255","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","volume":"4","author":"KA Autio","year":"2018","unstructured":"Autio, K. A. et al. Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 4, 1344\u20131351 (2018).","journal-title":"JAMA Oncol."},{"key":"1107_CR256","doi-asserted-by":"publisher","first-page":"22531","DOI":"10.18632\/oncotarget.8001","volume":"7","author":"M Michalska","year":"2016","unstructured":"Michalska, M. et al. In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer. Oncotarget 7, 22531\u201322542 (2016).","journal-title":"Oncotarget"},{"key":"1107_CR257","doi-asserted-by":"publisher","first-page":"113936","DOI":"10.1016\/j.ejmech.2021.113936","volume":"227","author":"AE Machulkin","year":"2022","unstructured":"Machulkin, A. E. et al. PSMA-targeted small-molecule docetaxel conjugate: synthesis and preclinical evaluation. Eur. J. Med. Chem. 227, 113936 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1107_CR258","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.omto.2020.06.014","volume":"18","author":"J Alzubi","year":"2020","unstructured":"Alzubi, J. et al. PSMA-Directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Mol. Ther. Oncolytics 18, 226\u2013235 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1107_CR259","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","volume":"21","author":"EA Lim","year":"2023","unstructured":"Lim, E. A. et al. Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer. Clin. Genitourin. Cancer 21, 366\u2013375 (2023).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1107_CR260","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24655-x","volume":"8","author":"SEA Burnell","year":"2018","unstructured":"Burnell, S. E. A. et al. STEAP2 knockdown reduces the invasive potential of prostate cancer cells. Sci. Rep. 8, 6252 (2018).","journal-title":"Sci. Rep."},{"key":"1107_CR261","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1002\/cncr.34433","volume":"128","author":"JW Lillard","year":"2022","unstructured":"Lillard, J. W., Moses, K. A., Mahal, B. A. & George, D. J. Racial disparities in Black men with prostate cancer: a literature review. Cancer 128, 3787\u20133795 (2022).","journal-title":"Cancer"},{"key":"1107_CR262","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1464-410X.2011.10365.x","volume":"108","author":"CG Roehrborn","year":"2011","unstructured":"Roehrborn, C. G. & Black, L. K. The economic burden of prostate cancer. BJU Int. 108, 806\u2013813 (2011).","journal-title":"BJU Int."},{"key":"1107_CR263","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12876-023-02793-5","volume":"23","author":"J Alonso","year":"2023","unstructured":"Alonso, J. et al. Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review. BMC Gastroenterol. 23, 181 (2023).","journal-title":"BMC Gastroenterol."},{"key":"1107_CR264","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/1450-1147.136694","volume":"12","author":"A Shinto","year":"2013","unstructured":"Shinto, A., Kamaleshwaran, K., Shibu, D., Vyshak, K. & Antony, J. Empiric therapy with low-dose I-131 in differentiated cancer thyroid: what is the magic number? World J. Nucl. Med. 12, 61\u201364 (2013).","journal-title":"World J. Nucl. Med."},{"key":"1107_CR265","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/UPJ.0000000000000363","volume":"10","author":"TA Olsen","year":"2023","unstructured":"Olsen, T. A., Filson, C. P., Richards, T. B., Ekwueme, D. U. & Howard, D. H. The cost of metastatic prostate cancer in the United States. Urol. Pract. 10, 41\u201347 (2023).","journal-title":"Urol. Pract."},{"key":"1107_CR266","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2967\/jnumed.118.218917","volume":"60","author":"H Rathke","year":"2019","unstructured":"Rathke, H. et al. Dosimetry estimate and initial clinical experience with 90Y-PSMA-617. J. Nucl. Med. 60, 806\u2013811 (2019).","journal-title":"J. Nucl. Med."},{"key":"1107_CR267","unstructured":"International Atomic Energy Agency. Therapeutic Radionuclide Generators: 90Sr\/90Yand 188W\/188Re Generators (IAEA, 2009)."},{"key":"1107_CR268","first-page":"190","volume":"61","author":"J Kurth","year":"2020","unstructured":"Kurth, J., Krause, B. J., Hakenberg, O., Schwarzenboeck, S. & Heuschkel, M. [90Y]Y-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer \u2014 post-therapeutic kidney and bone marrow dosimetry for individualized therapy. J. Nucl. Med. 61, 190 (2020).","journal-title":"J. Nucl. Med."},{"key":"1107_CR269","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500128","volume":"20","author":"MC Sobral","year":"2025","unstructured":"Sobral, M. C., Mota, S. I., Oliveira, P. J., Urbano, A. M. & Paulo, A. Two targets, one mission: heterobivalent metal-based radiopharmaceuticals for prostate cancer imaging and therapy. ChemMedChem 20, e202500128 (2025).","journal-title":"ChemMedChem"},{"key":"1107_CR270","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/BF00181067","volume":"21","author":"JMH de Klerk","year":"1994","unstructured":"de Klerk, J. M. H. et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur. J. Nucl. Med. 21, 1114\u20131120 (1994).","journal-title":"Eur. J. Nucl. Med."},{"key":"1107_CR271","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/sj.bjc.6601158","volume":"89","author":"K Liepe","year":"2003","unstructured":"Liepe, K., Kropp, J., Runge, R. & Kotzerke, J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br. J. Cancer 89, 625\u2013629 (2003).","journal-title":"Br. J. Cancer"},{"key":"1107_CR272","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/j.semnuclmed.2015.10.005","volume":"46","author":"S Evans-Axelsson","year":"2016","unstructured":"Evans-Axelsson, S., Timmermand, O. V., Bjartell, A., Strand, S.-E. & Elgqvist, J. Radioimmunotherapy for prostate cancer \u2014 current status and future possibilities. Semin. Nucl. Med. 46, 165\u2013179 (2016).","journal-title":"Semin. Nucl. Med."},{"key":"1107_CR273","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fmed.2019.00132","volume":"6","author":"N Lepareur","year":"2019","unstructured":"Lepareur, N. et al. Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives. Front. Med. 6, 132 (2019).","journal-title":"Front. Med."},{"key":"1107_CR274","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2967\/jnumed.122.264944","volume":"64","author":"J Cardinale","year":"2023","unstructured":"Cardinale, J. et al. PSMA-GCK01: a generator-based 99mTc\/188Re theranostic ligand for the prostate-specific membrane antigen. J. Nucl. Med. 64, 1069\u20131075 (2023).","journal-title":"J. Nucl. Med."},{"key":"1107_CR275","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41416-022-01881-9","volume":"127","author":"B Trujillo","year":"2022","unstructured":"Trujillo, B., Wu, A., Wetterskog, D. & Attard, G. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br. J. Cancer 127, 1394\u20131402 (2022).","journal-title":"Br. J. Cancer"},{"key":"1107_CR276","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","volume":"13","author":"DC Danila","year":"2007","unstructured":"Danila, D. C. et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13, 7053\u20137058 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1107_CR277","doi-asserted-by":"publisher","first-page":"599602","DOI":"10.3389\/fonc.2021.599602","volume":"11","author":"H Liu","year":"2021","unstructured":"Liu, H., Gao, Y., Vafaei, S., Gu, X. & Zhong, X. The prognostic value of plasma cell-free DNA concentration in the prostate cancer: a systematic review and meta-analysis. Front. Oncol. 11, 599602 (2021).","journal-title":"Front. Oncol."},{"key":"1107_CR278","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.eururo.2018.12.042","volume":"75","author":"G Vandekerkhove","year":"2019","unstructured":"Vandekerkhove, G. et al. Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer. Eur. Urol. 75, 667\u2013675 (2019).","journal-title":"Eur. Urol."},{"key":"1107_CR279","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41416-021-01508-5","volume":"125","author":"U De Giorgi","year":"2021","unstructured":"De Giorgi, U. et al. Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. Br. J. Cancer 125, 1226\u20131232 (2021).","journal-title":"Br. J. Cancer"},{"key":"1107_CR280","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/cells8070688","volume":"8","author":"M Nimir","year":"2019","unstructured":"Nimir, M. et al. Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients: a comparison of AR-V7 analysis in circulating tumor cells, circulating tumor RNA and exosomes. Cells 8, 688 (2019).","journal-title":"Cells"},{"key":"1107_CR281","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/13696998.2023.2183618","volume":"26","author":"SW Quist","year":"2023","unstructured":"Quist, S. W., Paulissen, J. H. J., Wyndaele, D. N. J., Nagarajah, J. & Freriks, R. D. Costs of radium-223 and the pharmacy preparation 177Lu-PSMA-I&T for metastatic castration-resistant prostate cancer in Dutch hospitals. J. Med. Econ. 26, 366\u2013375 (2023).","journal-title":"J. Med. Econ."},{"key":"1107_CR282","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2022.7070","volume":"21","author":"D Mehrens","year":"2023","unstructured":"Mehrens, D. et al. Cost-effectiveness analysis of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer. J. Natl Compr. Cancer Netw. 21, 43\u201350.e2 (2023).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1107_CR283","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00259-021-05392-2","volume":"48","author":"WV Vogel","year":"2021","unstructured":"Vogel, W. V., van der Marck, S. C. & Versleijen, M. W. J. Challenges and future options for the production of lutetium-177. Eur. J. Nucl. Med. Mol. Imaging 48, 2329\u20132335 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1107_CR284","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","volume":"5","author":"S Fanti","year":"2022","unstructured":"Fanti, S. et al. EAU-EANM consensus statements on the role of prostate-specific membrane antigen positron emission tomography\/computed tomography in patients with prostate cancer and with respect to [177Lu]Lu-PSMA radioligand therapy. Eur. Urol. Oncol. 5, 530\u2013536 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"1107_CR285","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40273-022-01156-4","volume":"40","author":"R Song","year":"2022","unstructured":"Song, R., Jeet, V., Sharma, R., Hoyle, M. & Parkinson, B. Cost-effectiveness analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography\/Computed Tomography (PET\/CT) for the primary staging of prostate cancer in Australia. Pharmacoeconomics 40, 807\u2013821 (2022).","journal-title":"Pharmacoeconomics"},{"key":"1107_CR286","doi-asserted-by":"publisher","first-page":"1070497","DOI":"10.3389\/fmed.2022.1070497","volume":"9","author":"E Ostuni","year":"2022","unstructured":"Ostuni, E. & Taylor, M. R. G. Commercial and business aspects of alpha radioligand therapeutics. Front. Med. 9, 1070497 (2022).","journal-title":"Front. Med."},{"key":"1107_CR287","unstructured":"National Institute for Health and Care Excellence. Lutetium-177 Vipivotide Tetraxetan for Treating PSMA-Positive Hormone-Relapsed Metastatic Prostate Cancer after 2 or More Treatments (NICE, 2023)."},{"key":"1107_CR288","unstructured":"Thevenot, L. I. & Jacobson, G. M. ASTRO Letter to FDA re Pluvicto 3 14 2023__signed (ASTRO, 2023)."},{"key":"1107_CR289","unstructured":"Novartis. Novartis expands production of Pluvicto with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis. Novartis https:\/\/www.novartis.com\/news\/media-releases\/novartis-expands-production-pluvictotm-addition-its-largest-and-most-advanced-radioligand-therapy-manufacturing-facility-indianapolis (2024)."},{"key":"1107_CR290","unstructured":"Bessette, Z. FDA approves Lutetium-177-PSMA-617 production at New Jersey facility. GU Oncology Now https:\/\/www.guoncologynow.com\/post\/fda-approves-lutetium-177-psma-617-production-at-new-jersey-facility (2023)."},{"key":"1107_CR291","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s00259-023-06139-x","volume":"50","author":"L Flegar","year":"2023","unstructured":"Flegar, L. et al. Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020. Eur. J. Nucl. Med. Mol. Imaging 50, 2188\u20132195 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1107_CR292","unstructured":"Genesiscare. PSMA PET-CT scan. Genesiscare https:\/\/www.genesiscare.com\/uk\/diagnostics\/imaging-scans\/pet-ct-scan\/68gallium-psma-pet-ct-scan.%20Accessed%207th%20June,%202025 (2024)."},{"key":"1107_CR293","unstructured":"Africa Infoline. PET CT scan cost in African cities. Africa Infoline https:\/\/africainfoline.com\/listing\/scans\/africa\/pet-ct-scan-cost-in-african-cities-find-best-hospital-and-book-appointment (2025)."},{"key":"1107_CR294","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41591-022-01738-x","volume":"28","author":"CS Pramesh","year":"2022","unstructured":"Pramesh, C. S. et al. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat. Med. 28, 649\u2013657 (2022).","journal-title":"Nat. Med."},{"key":"1107_CR295","doi-asserted-by":"publisher","first-page":"pkae059","DOI":"10.1093\/jncics\/pkae059","volume":"8","author":"M Di","year":"2024","unstructured":"Di, M. et al. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectr. 8, pkae059 (2024).","journal-title":"JNCI Cancer Spectr."},{"key":"1107_CR296","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/RLU.0000000000002575","volume":"44","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Pretherapeutic 68Ga-PSMA-617 PET may indicate the dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in main organs and tumor lesions. Clin. Nucl. Med. 44, 431\u2013438 (2019).","journal-title":"Clin. Nucl. Med."},{"key":"1107_CR297","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MNM.0000000000000606","volume":"38","author":"MP Yadav","year":"2017","unstructured":"Yadav, M. P. et al. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl. Med. Commun. 38, 91\u201398 (2017).","journal-title":"Nucl. Med. Commun."},{"key":"1107_CR298","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-021-00385-4","volume":"8","author":"F Rosar","year":"2021","unstructured":"Rosar, F. et al. Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys. 8, 40 (2021).","journal-title":"EJNMMI Phys."},{"key":"1107_CR299","unstructured":"Society of Nuclear Medicine and Molecular Imaging. 177Lu PSMA-617 therapy (Pluvicto). SNMMI https:\/\/snmmi.org\/AM\/Patients\/Procedures\/177Lu-PSMA-617-Therapy-Pluvicto.aspx (2022)."},{"key":"1107_CR300","doi-asserted-by":"publisher","first-page":"102748","DOI":"10.1016\/j.ctrv.2024.102748","volume":"127","author":"M Muniz","year":"2024","unstructured":"Muniz, M. et al. Salivary toxicity from PSMA-targeted radiopharmaceuticals: what we have learned and where we are going. Cancer Treat. Rev. 127, 102748 (2024).","journal-title":"Cancer Treat. Rev."},{"key":"1107_CR301","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bju.15491","volume":"128","author":"L Emmett","year":"2021","unstructured":"Emmett, L. et al. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int. 128, 642\u2013651 (2021).","journal-title":"BJU Int."},{"key":"1107_CR302","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1200\/JCO.2022.40.6_suppl.097","volume":"40","author":"K Herrmann","year":"2022","unstructured":"Herrmann, K. et al. Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study. J. Clin. Oncol. 40, 97\u201397 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1107_CR303","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03454750 (2025)."},{"key":"1107_CR304","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00259-019-04583-2","volume":"47","author":"J Maffey-Steffan","year":"2020","unstructured":"Maffey-Steffan, J. et al. The 68Ga\/177Lu-theragnostic concept in PSMA-targeting of metastatic castration\u2013resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur. J. Nucl. Med. Mol. Imaging 47, 695\u2013712 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1107_CR305","doi-asserted-by":"publisher","first-page":"940677","DOI":"10.3389\/fphy.2022.940677","volume":"10","author":"R Alsadi","year":"2022","unstructured":"Alsadi, R., Djekidel, M., Bouhali, O. & Doherty, J. O. Towards routine clinical use of dosimetry in [177Lu]Lu-PSMA prostate cancer radionuclide therapy: current efforts and future perspectives. Front. Phys. 10, 940677\u00a0(2022).","journal-title":"Front. Phys."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01107-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:03:47Z","timestamp":1780920227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01107-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":305,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1038\/s41585-025-01107-6","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"13 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.H. acknowledges philanthropic\/government grant support from the Prostate Cancer Foundation (PCF), including CANICA Oslo Norway, Peter MacCallum Foundation and NHMRC Investigator Grant; other funding in the past 10 years\u00a0from Movember\/Medical Research Future Fund (MRFF), US Department of Defense and the Prostate Cancer Foundation of Australia (PCFA); research grant support (to Peter MacCallum Cancer Centre) from Novartis, ANSTO, Bayer, Isotopia and MIM; and\u00a0consulting fees for lectures or advisory boards from Janssen and MSD in the past 2 years\u00a0and AstraZeneca, Astellas and Mundipharma in the past 5 years. T.S.Y. receives research funding support from AbbVie. G.J.R.C. receives research support from Theragnostics, NanoMab Technology (UK) and Siemens Healthineers; provides consultancy and advisory board support to Serac Healthcare, Amgen, Telix\u00a0Pharmaceuticals, Blue Earth Diagnostics, NanoMab Technology (UK), GE Healthcare and Full Life Technology; and receives lecture fees from Telix Pharmaceuticals\u00a0and Curium. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}